These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients. Shafi T; Hostetter TH; Meyer TW; Hwang S; Hai X; Melamed ML; Banerjee T; Coresh J; Powe NR Am J Kidney Dis; 2017 Jul; 70(1):48-58. PubMed ID: 28089476 [TBL] [Abstract][Full Text] [Related]
8. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Böger RH; Zoccali C Atheroscler Suppl; 2003 Dec; 4(4):23-8. PubMed ID: 14664899 [TBL] [Abstract][Full Text] [Related]
9. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology? Busch M; Fleck C; Wolf G; Stein G Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555 [TBL] [Abstract][Full Text] [Related]
10. Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA. Boelaert J; Schepers E; Glorieux G; Eloot S; Vanholder R; Lynen F Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27187471 [TBL] [Abstract][Full Text] [Related]
11. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Schulze F; Carter AM; Schwedhelm E; Ajjan R; Maas R; von Holten RA; Atzler D; Grant PJ; Böger RH Atherosclerosis; 2010 Feb; 208(2):518-23. PubMed ID: 19700158 [TBL] [Abstract][Full Text] [Related]
12. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases. Böger RH; Bode-Böger SM Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410 [TBL] [Abstract][Full Text] [Related]
13. The methylarginines NMMA, ADMA, and SDMA are ubiquitous constituents of the main vegetables of human nutrition. Servillo L; Giovane A; Cautela D; Castaldo D; Balestrieri ML Nitric Oxide; 2013 Apr; 30():43-8. PubMed ID: 23438481 [TBL] [Abstract][Full Text] [Related]
14. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study. Aucella F; Maas R; Vigilante M; Tripepi G; Schwedhelm E; Margaglione M; Gesualdo L; Boeger R; Zoccali C Atherosclerosis; 2009 Dec; 207(2):541-5. PubMed ID: 19501358 [TBL] [Abstract][Full Text] [Related]
15. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Kielstein JT; Zoccali C Am J Kidney Dis; 2005 Aug; 46(2):186-202. PubMed ID: 16112037 [TBL] [Abstract][Full Text] [Related]
16. Association of asymmetric dimethylarginine and endothelial dysfunction. Böger RH Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027 [TBL] [Abstract][Full Text] [Related]
17. Level of asymmetric dimethylarginine and carotid atherosclerosis in patients with chronic kidney disease. Zhang WR; Hou FF; Ning JP; Yang XB; Wu Q; Tao LJ; Chen BM; Li HY; Chang L Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):621-8. PubMed ID: 17062918 [TBL] [Abstract][Full Text] [Related]
18. Plasma asymmetric dimethylarginine, symmetric dimethylarginine, l-arginine, and nitrite/nitrate concentrations in cats with chronic kidney disease and hypertension. Jepson RE; Syme HM; Vallance C; Elliott J J Vet Intern Med; 2008; 22(2):317-24. PubMed ID: 18371026 [TBL] [Abstract][Full Text] [Related]
19. Role of asymmetrical dimethylarginine in the progression of renal disease. Raptis V; Kapoulas S; Grekas D Nephrology (Carlton); 2013 Jan; 18(1):11-21. PubMed ID: 23016674 [TBL] [Abstract][Full Text] [Related]
20. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Ueda S; Yamagishi S; Kaida Y; Okuda S Nephrology (Carlton); 2007 Dec; 12(6):582-90. PubMed ID: 17995585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]